RxDoctor Payments Data

Benjamin Whitt, MD

Infectious Disease · Spartanburg, SCNPI 1447755145

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Gilead at 39.6% of the total.

$1,252in general payments, 2019–2025

Across 62 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$496
  • Viiv Healthcare Company$245
  • AbbVie$91
  • Shionogi Inc$71
  • Merck$71
  • Melinta Therapeutics, LLC$64
  • plus $214 from 9 others

What the payments were for

  • Food & beverage$1,23599%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,252 in reported general payments places this provider in the 55th percentile of 102 infectious disease providers in South Carolina.

See all infectious disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$57,094
Medicare patients
152
Services billed
670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir19$449,933
BiktarvyBictegrav/Emtricit/Tenofov Ala47$178,289
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf21$92,985
DovatoDolutegravir Sodium/Lamivudine13$36,741
Cefepime Hcl12$1,974
Linezolid13$1,032
Vancomycin Hcl13$921
Ethambutol Hcl18$817
Methenamine Hippurate16$760
Fluconazole39$641
Rifampin18$589
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$541
Doxycycline Monohydrate19$502
CeftriaxoneCeftriaxone Sodium12$379
Cefadroxil14$246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Biktarvy$496$628,22166 claims
Viiv Healthcare CompanyDovato$245$36,74113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 102 infectious disease providers in South Carolina.

Other infectious disease in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →